Clinical outcomes of atrial fibrillation patients with increase in HAS-BLED score and discontinue oral anticoagulants
Thrombosis and Haemostasis · 10.03.2026
DOI: 10.1055/a-2815-5300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 10.03.2026. Verfasst von Voravut Rungpradubvong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Gefördert von: Health Systems Research Institute, Heart Association of Thailand.
Abstract (Originalsprache)
Background
We examined the association of oral anticoagulants (OAC) discontinuation following a rise in HAS-BLED score among patients enrolled in a nationwide AF registry.
Methods
We analyzed 1,030 patients from the prospective, multicenter COOL-AF registry who were receiving OACs at baseline and subsequently experienced an increase in HAS-BLED score. Patients were categorized according to OAC continuation (n = 936) or discontinuation (n = 94) at the time of score increase. The primary composite outcome included all-cause mortality, stroke/systemic embolism (SSE), and major bleeding. Multivariable Cox regression and propensity score matching (1:2) were performed to adjust for confounders.
Results
During a median follow-up of 23.7 months (IQR 13.3-29.9), patients who discontinued OACs had substantially higher event rates than those who continued therapy (20.2 vs 7.9 per 100 person-years; p < 0.001). OAC discontinuation independently associated with an increased risk of the composite endpoint (adjusted HR 2.65, 95% CI 1.75–4.02; p < 0.001), all-cause mortality (aHR 3.66, 95% CI 2.25–5.96; p < 0.001), and major bleeding (aHR 2.60, 95% CI 1.27–5.33; p = 0.009), without a significant difference in SSE (aHR 0.39, 95% CI 0.05–2.89). Findings were confirmed in the propensity-matched cohort. No significant difference in stroke/systemic embolism was observed, potentially reflecting competing mortality risk and residual confounding inherent to the observational design.
Conclusions
OAC discontinuation after a HAS-BLED score increase was associated with worse outcomes, likely reflecting residual confounding rather than a direct causal effect, and should prompt risk optimization rather than automatic cessation.
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Cardiac Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Medical University of Bialystok, Bialystok, Poland.
- Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Gregory Y H Lip
Förderung
- Health Systems Research Institute
- Heart Association of Thailand
Zitieren
APA
Rungpradubvong, V., Lip, G. Y. H., & Krittayaphong, R. (2026). Clinical outcomes of atrial fibrillation patients with increase in HAS-BLED score and discontinue oral anticoagulants. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2815-5300
Vancouver
Rungpradubvong V, Lip GYH, Krittayaphong R. Clinical outcomes of atrial fibrillation patients with increase in HAS-BLED score and discontinue oral anticoagulants. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2815-5300
BibTeX
@article{Rungpradubvong2026,
author = {Rungpradubvong, Voravut and Lip, Gregory Y H and Krittayaphong, Rungroj},
title = {Clinical outcomes of atrial fibrillation patients with increase in HAS-BLED score and discontinue oral anticoagulants},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2815-5300}
}
EUVIMED